Aggressive hematologic malignancy publications can be challenging to interpret and translate to clinical practice.
We look at two recent studies to illustrate this point.
Elderly AML: 10-day decitabine vs. 7 + 3 (https://doi.org/10.1016/S2352-3026(23)00273-9)
Burkitt Lymphoma: R-CODXO-M/R-IVAC vs. DA-R-EPOCH (https://doi.org/10.1016/S2352-3026(23)00279-X)
